Department of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia University, Morgantown, West Virginia 26506-9510, USA.
Pharmacoeconomics. 2010;28(3):201-16. doi: 10.2165/11313990-000000000-00000.
Preference-based measures of health (PBMH) provide 'preference' or 'utility' weights that enable the calculation of QALYs for the economic evaluations of interventions. The Diabetes Utility Index (DUI) was developed as a brief, self-administered, diabetes mellitus-specific PBMH that can efficiently estimate patient-derived health state utilities. To describe the development of the valuation function for the DUI, and to report the validation results of the valuation function. Multi-Attribute Utility Theory (MAUT) was used as the framework to develop a valuation function for the DUI. Twenty of 768 possible health states of the DUI classified as anchor states, single-attribute level states including corner states, and marker states were selected and described for preference elicitation interviews. Visual analogue scale and standard gamble (SG) exercises were used to measure preferences from individuals with diabetes recruited from primary care and community settings in and around Morgantown, WV, USA for the 20 health states defined by combinations of DUI attributes and severity levels. Data collected in the interviews were used to develop a valuation function that calculates utilities for the DUI health states and calculates attribute-level utilities. A validation survey of the valuation function was conducted in collaboration with the West Virginia University (WVU) Diabetes Institute. A total of 100 individuals with diabetes were interviewed and their preferences for various DUI health states measured. From data generated in the interviews, a DUI valuation function was developed on a scale where 1.00 = perfect health (PH) and 0.00 = the all worse 'pits' state, and adjusted to yield utilities on the conventional scale 1.00 = PH and 0.00 = dead. A total of 396 patients with diabetes who received care at WVU clinics completed a DUI mail validation survey (response rate = 33%). Clinical data consisting of International Classification of Diseases, 9th edition, diagnosis codes and glycosylated haemoglobin (HbA(1c)) values for the respondents were merged with their responses to the DUI. The utilities calculated by the scoring function of the DUI compared favourably to cardinal SG utilities for three DUI health states for which both assessments were available. The DUI utility function slightly underestimated actual SG utilities for mild and moderate health states (mean absolute difference = 0.05). There was a small but significant correlation between DUI utility scores and average past year HbA(1c) values (r = -0.30; p < 0.001). Respondents with two or more complications had significantly lower DUI utilities than those with no complications (p < 0.001) or one complication (p = 0.015). Insulin users had significantly lower DUI utilities than non-users (p < 0.001), and those with HbA(1c) values <7% had significantly higher DUI utilities than those with HbA(1c) values of >or=7% (p < 0.001). No significant association was found between DUI scores and age or sex. These results show evidence of the feasibility and validity of the DUI. Further research is suggested to demonstrate the generalizability of these findings, to study the responsiveness of the DUI, and to examine the clinical meaningfulness of DUI change scores.
偏好加权健康测量(PBMH)提供“偏好”或“效用”权重,使能够对干预措施进行经济评估的 QALY 计算。糖尿病效用指数(DUI)是作为一种简短的、自我管理的、专门针对糖尿病的 PBMH 开发的,可有效地估计患者来源的健康状态效用。本文描述了 DUI 的估值函数的开发,并报告了估值函数的验证结果。多属性效用理论(MAUT)被用作开发 DUI 估值函数的框架。从 768 个可能的 DUI 健康状态中选择了 20 个,这些健康状态被归类为锚定状态、单属性水平状态(包括角状态和标记状态),并进行了描述,以进行偏好 elicitation 访谈。视觉模拟量表和标准博弈(SG)练习用于从美国西弗吉尼亚州摩根敦及其周边地区的初级保健和社区环境中招募的糖尿病患者中测量偏好。从访谈中收集的数据用于开发一个估值函数,该函数为 DUI 健康状态计算效用,并计算属性级别的效用。与西弗吉尼亚大学(WVU)糖尿病研究所合作进行了对估值函数的验证调查。共对 100 名糖尿病患者进行了访谈,并测量了他们对各种 DUI 健康状态的偏好。从访谈中生成的数据开发了一个 DUI 估值函数,该函数的范围为 1.00=完美健康(PH)和 0.00=所有更差的“坑”状态,并进行了调整,以产生传统范围内的效用 1.00=PH 和 0.00=死亡。共有 396 名在 WVU 诊所接受治疗的糖尿病患者完成了 DUI 邮件验证调查(响应率=33%)。受访者的国际疾病分类,第 9 版诊断代码和糖化血红蛋白(HbA(1c))值与他们对 DUI 的反应合并在一起。由 DUI 评分函数计算的效用与三个 DUI 健康状态的基数 SG 效用相当,这三个状态都有评估。对于轻度和中度健康状态,DUI 效用函数略微低估了实际 SG 效用(平均绝对差异=0.05)。DUI 效用得分与过去一年平均 HbA(1c)值之间存在很小但显著的相关性(r=-0.30;p<0.001)。有两个或更多并发症的患者的 DUI 效用明显低于没有并发症(p<0.001)或有一个并发症(p=0.015)的患者。使用胰岛素的患者的 DUI 效用明显低于非使用者(p<0.001),HbA(1c)值<7%的患者的 DUI 效用明显高于 HbA(1c)值≥7%的患者(p<0.001)。没有发现 DUI 分数与年龄或性别之间存在显著关联。这些结果表明 DUI 的可行性和有效性。建议进一步研究以证明这些发现的普遍性,研究 DUI 的反应性,并检查 DUI 变化分数的临床意义。